SomaLogic (SLGC) and The Competition Critical Contrast

SomaLogic (NASDAQ:SLGCGet Rating) is one of 42 publicly-traded companies in the “Commercial physical research” industry, but how does it weigh in compared to its peers? We will compare SomaLogic to similar companies based on the strength of its valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

Analyst Ratings

This is a breakdown of current recommendations for SomaLogic and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SomaLogic 0 0 4 0 3.00
SomaLogic Competitors 42 622 1215 24 2.64

SomaLogic currently has a consensus target price of $12.20, indicating a potential upside of 292.28%. As a group, “Commercial physical research” companies have a potential upside of 53.98%. Given SomaLogic’s stronger consensus rating and higher probable upside, research analysts clearly believe SomaLogic is more favorable than its peers.

Insider and Institutional Ownership

59.3% of SomaLogic shares are owned by institutional investors. Comparatively, 58.4% of shares of all “Commercial physical research” companies are owned by institutional investors. 12.9% of SomaLogic shares are owned by company insiders. Comparatively, 11.9% of shares of all “Commercial physical research” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares SomaLogic and its peers gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
SomaLogic $81.63 million -$87.55 million -3.75
SomaLogic Competitors $2.80 billion $97.54 million -14.48

SomaLogic’s peers have higher revenue and earnings than SomaLogic. SomaLogic is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

SomaLogic has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500. Comparatively, SomaLogic’s peers have a beta of 5.23, indicating that their average share price is 423% more volatile than the S&P 500.


This table compares SomaLogic and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SomaLogic -114.46% -16.76% -14.61%
SomaLogic Competitors -239.39% -12.45% -6.19%


SomaLogic beats its peers on 7 of the 13 factors compared.

About SomaLogic

(Get Rating)

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal research use only and laboratory-developed tests. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions, as well as facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.

Receive News & Ratings for SomaLogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SomaLogic and related companies with's FREE daily email newsletter.